ST is correct that previous statements have been in excess of $200m - these where made quite some time ago & much has also changed in this time.
I hope they drag it out over a longer period, i am more interested in seeing the company continue to build & increase value as progress is made than any near term take-over. The more partnerships Phylogica sign & the further these advance the higher value that needs to be attributed by a potential suiter. The remaining 3 partnerships for 2011 & Roche re-structure will add the weight IMO.
What i really want to know, and i have stated before is that Caris&Company now have a vested interest through acting as the US placement agent & now play an active role. The discounted placement would be a small sum to pay to have their weight now secured behind Phylogica.
Caris & Company
Private Equity
Caris & Company's investment bankers act as private placement agents for emerging, small-cap and middle market corporations seeking to raise private equity capital through the sale of equity, equity-related and debt securities in the strategic corporate, private equity and venture capital markets.
Our investment bankers invest significantly in building and maintaining active relationships with private equity, venture capital, and strategic investors within our focus industries where we are recognized for our ability to closely match issuers with investors.
Whether for seeking growth or acquisition capital or for seeking to recapitalize a company to achieve shareholder liquidity or a shareholder buyout, we leverage our knowledge of the private equity capital- raising process and markets to provide corporate clients with strategic guidance and professional advice regarding capital formation and structure, timing, securities valuation, pricing, and terms.
Mergers & Acquisitions
Caris & Companys merger and acquisition (M&A) professionals provide buy-side and sell-side advice and representation to small-cap and middle market companies ranging in size from $10 million to $1 billion.
With decades of experience advising both sellers and buyers on M&A transactions, our investment bankers are highly skilled and experienced throughout the entire process of selling or buying a company from the early planning stages through the closing. They are seasoned dealmakers who bring to bear extensive experience in valuation, deal structuring, and negotiations to achieve maximum value in both price and terms for our clients.
- Forums
- ASX - By Stock
- and the outcome of the convertible note is ? ?
PYC
pyc therapeutics limited
Add to My Watchlist
2.51%
!
$1.36

ST is correct that previous statements have been in excess of...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.36 |
Change
-0.035(2.51%) |
Mkt cap ! $793.2M |
Open | High | Low | Value | Volume |
$1.39 | $1.43 | $1.36 | $169.8K | 122.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 9675 | $1.36 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.45 | 2801 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 9675 | 1.360 |
2 | 11414 | 1.350 |
3 | 7878 | 1.340 |
1 | 692 | 1.300 |
1 | 196 | 1.275 |
Price($) | Vol. | No. |
---|---|---|
1.445 | 2801 | 1 |
1.450 | 16369 | 3 |
1.465 | 20000 | 1 |
1.470 | 16036 | 3 |
1.475 | 20000 | 1 |
Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online